[Methods to evaluate aspirin and clopidogrel resistance]

Area of Science:

• Pharmacology
• Clinical Chemistry
• Hematology

Background:

• Resistance to anti-platelet drugs is often defined by a lack of pharmacodynamic effect at the drug's target.
• Current assays for evaluating anti-platelet drug efficacy may not always reflect direct pharmacodynamic actions.
• Accurate assessment of drug response is crucial for patient management and therapeutic optimization.

Purpose of the Study:

• To propose a framework for selecting appropriate assays to evaluate anti-platelet drug effects.
• To emphasize the importance of measuring direct pharmacodynamic targets for accurate resistance assessment.
• To provide specific assay recommendations for aspirin and clopidogrel.

Main Methods:

• Review of the pharmacodynamic mechanisms of common anti-platelet agents.
• Identification of direct molecular targets and downstream signaling pathways.
• Correlation of drug targets with measurable biochemical or cellular responses.

Main Results:

• For aspirin, direct pharmacodynamic assessment involves measuring thromboxane concentrations or arachidonic acid-induced platelet aggregation.
• For clopidogrel, direct pharmacodynamic assessment involves analyzing VASP phosphorylation via flow cytometry or ADP-induced platelet aggregation.
• These specific assays directly reflect the drugs' mechanisms of action, differentiating them from non-specific platelet function tests.

Conclusions:

• Assays measuring direct pharmacodynamic effects are essential for accurate assessment of anti-platelet drug resistance.
• Specific, target-based assays for aspirin and clopidogrel provide a more precise evaluation of drug efficacy.
• Implementing these targeted assays can improve the clinical understanding and management of patients on anti-platelet therapy.